Table 3.

Pending Phase 2 or Phase 3 trials of PARP inhibition in Prostate Cancer with HRD.

ClinicalTrials.Gov #	Phase	Investigational Agent	Population
NCT02987543	3	Olaparib vs Standard Treatment (Enzalutamide or Abiraterone)	mCRPC with HRD, second-line therapy
NCT03012321	2	Olaparib plus Abiraterone vs Olaparib vs Abiraterone	mCRPC with HRD, first line therapy
NCT02975934	3	Rucaparib vs Standard Treatment (Physician’s Choice)	mCPRC with BRCA1, BRCA2, or ATM mutation; second-line therapy
NCT02952534	2	Rucaparib	mCRPC with HRD, third- or fourth-line therapy
NCT02854436	2	Niraparib	mCPRC with HRD, third-line or beyond therapy
NCT02987543	2	Talazoparib	mCRPC with BRCA1 or BRCA2 mutation, third-line therapy
NCT03047135	2	Olaparib	Biochemically recurrent prostate cancer, hormone-naïve